461 related articles for article (PubMed ID: 31910643)
1. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
[No Abstract] [Full Text] [Related]
2. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.
Pialoux G; Marcelin AG; Cawston H; Guilmet C; Finkielsztejn L; Laurisse A; Aubin C
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):83-91. PubMed ID: 28741965
[TBL] [Abstract][Full Text] [Related]
4. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Trottier B; Lake JE; Logue K; Brinson C; Santiago L; Brennan C; Koteff JA; Wynne B; Hopking J; Granier C; Aboud M
Antivir Ther; 2017; 22(4):295-305. PubMed ID: 28401876
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.
Suárez-García I; Alejos B; Ruiz-Algueró M; García Yubero C; Moreno C; Bernal E; Pérez-Is L; Zubero Z; de Zárraga Fernández MA; Samperiz Abad G; Jarrín I;
J Int AIDS Soc; 2021 Jul; 24(7):e25758. PubMed ID: 34291580
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
Tremblay G; Chounta V; Piercy J; Holbrook T; Garib SA; Bukin EK; Punekar YS
Value Health Reg Issues; 2018 Sep; 16():74-80. PubMed ID: 30296624
[TBL] [Abstract][Full Text] [Related]
9. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
10. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
Michienzi SM; Schriever CA; Badowski ME
Int J STD AIDS; 2019 Feb; 30(2):181-187. PubMed ID: 30381029
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
Mondi A; Cozzi-Lepri A; Tavelli A; Rusconi S; Vichi F; Ceccherini-Silberstein F; Calcagno A; De Luca A; Maggiolo F; Marchetti G; Antinori A; d'Arminio Monforte A;
J Int AIDS Soc; 2019 Jan; 22(1):e25227. PubMed ID: 30663278
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
Butler K; Anderson SJ; Hayward O; Jacob I; Punekar YS; Evitt LA; Oglesby A
J Manag Care Spec Pharm; 2021 Jul; 27(7):891-903. PubMed ID: 34185564
[No Abstract] [Full Text] [Related]
15. Dolutegravir, abacavir and lamivudine as HIV therapy.
Fernandez-Montero JV; Barreiro P; Labarga P; De Mendoza C; Soriano V
Expert Opin Pharmacother; 2014 May; 15(7):1051-7. PubMed ID: 24754315
[TBL] [Abstract][Full Text] [Related]
16. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
[TBL] [Abstract][Full Text] [Related]
18. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL; Deeks ED
Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
Hocqueloux L; Raffi F; Prazuck T; Bernard L; Sunder S; Esnault JL; Rey D; Le Moal G; Roncato-Saberan M; André M; Billaud E; Valéry A; Avettand-Fènoël V; Parienti JJ; Allavena C;
Clin Infect Dis; 2019 Oct; 69(9):1498-1505. PubMed ID: 30601976
[TBL] [Abstract][Full Text] [Related]
20. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
